Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis

Adam Reich; Jacek Szepietowski; Zygmunt Adamski; Grażyna Chodorowska; Andrzej Kaszuba; Dorota Krasowska; Aleksandra Lesiak; Joanna Maj; Joanna Narbutt; Agnieszka Osmola-Mańkowska; Agnieszka Owczarczyk-Saczonek; Witold Owczarek; Waldemar Placek; Lidia Rudnicka

doi:10.5114/dr.2018.77107

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2018
vol. 105

Send email

Copy url:

abstract:

Special paper

Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis

Adam Reich

,

Jacek Szepietowski

,

Zygmunt Adamski

,

Grażyna Chodorowska

,

Andrzej Kaszuba

,

Dorota Krasowska

,

Aleksandra Lesiak

,

Joanna Maj

,

Joanna Narbutt

,

Agnieszka Osmola-Mańkowska

,

Agnieszka Owczarczyk-Saczonek

,

Witold Owczarek

,

Waldemar Placek

,

Lidia Rudnicka

Dermatol Rev/Przegl Dermatol 2018, 105, 329–357

DOI: https://doi.org/10.5114/dr.2018.77107

Online publish date: 2018/07/20

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Reich A, Szepietowski J, Adamski Z, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis. Dermatology Review/Przegląd Dermatologiczny. 2018;105(3):329-357. doi:10.5114/dr.2018.77107.

APA

Reich, A., Szepietowski, J., Adamski, Z., Chodorowska, G., Kaszuba, A.,  & Krasowska, D. et al. (2018). Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis. Dermatology Review/Przegląd Dermatologiczny, 105(3), 329-357. https://doi.org/10.5114/dr.2018.77107

Chicago

Reich, Adam, Jacek Szepietowski, Zygmunt Adamski, Grażyna Chodorowska, Andrzej Kaszuba, Dorota Krasowska,  and Aleksandra Lesiak et al. 2018. "Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis". Dermatology Review/Przegląd Dermatologiczny 105 (3): 329-357. doi:10.5114/dr.2018.77107.

Harvard

Reich, A., Szepietowski, J., Adamski, Z., Chodorowska, G., Kaszuba, A., Krasowska, D., Lesiak, A., Maj, J., Narbutt, J., Osmola-Mańkowska, A., Owczarczyk-Saczonek, A., Owczarek, W., Placek, W.,  and Rudnicka, L. (2018). Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis. Dermatology Review/Przegląd Dermatologiczny, 105(3), pp.329-357. https://doi.org/10.5114/dr.2018.77107

MLA

Reich, Adam et al. "Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis." Dermatology Review/Przegląd Dermatologiczny, vol. 105, no. 3, 2018, pp. 329-357. doi:10.5114/dr.2018.77107.

Vancouver

Reich A, Szepietowski J, Adamski Z, Chodorowska G, Kaszuba A, Krasowska D et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis. Dermatology Review/Przegląd Dermatologiczny. 2018;105(3):329-357. doi:10.5114/dr.2018.77107.

PlumX metrics:

The second part of diagnostic and therapeutic guidelines of Polish Dermatological Society focuses on moderate and severe psoriasis, in which phototherapy or systemic treatment should be initiated. Currently, it is recommended to treat moderate to severe plaque psoriasis with either classic anti-psoriatic drugs (methotrexate, cyclosporine, acitretin), TNF--inhibitors (adalimumab, etanercept, infliximab), interleukin 12/23 blocking agent (ustekinumab) and new drugs – interleukin-17 inhibitors (secukinumab, ixekizumab) or interleukin 23 inhibitors (guselkumab, tildrakizumab), as well as the new low-molecular weight agents (apremilast, dimethyl fumarate). In some patients, UV-based therapy may be advisable. These recommendations summarize the principles of the use of these agents in patients with psoriasis in dermatological practice. The efficacy and safety of therapy is discussed and available methods to prevent adverse events are summarized.

keywords:

Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis

Adam Reich , Jacek Szepietowski , Zygmunt Adamski , Grażyna Chodorowska , Andrzej Kaszuba , Dorota Krasowska , Aleksandra Lesiak , Joanna Maj , Joanna Narbutt , Agnieszka Osmola-Mańkowska , Agnieszka Owczarczyk-Saczonek , Witold Owczarek , Waldemar Placek , Lidia Rudnicka

diagnostics, treatment, psoriasis, guidelines, consensus